TABLE 1.
All participants | Jan. 2016–Mar. 2020 | April 2020–Jun. 2022 | P value | |
---|---|---|---|---|
N | 587 | 351 | 236 | |
Diagnosis | 0.6 | |||
Crohn disease (CD) | 399 (68.0%) | 238 (67.8%) | 161 (68.2%) | |
Ulcerative colitis (UC) | 159 (27.1%) | 98 (27.9%) | 61 (25.8%) | |
Undetermined | 29 (4.9%) | 15 (4.3%) | 14 (5.9%) | |
Quarterly CD cases | Mean 15.3 (variance 34.3) | Mean 14.0 (variance 21.4) | Mean 17.7 (variance 54.5) | 0.2 |
Median 14.5, IQR (11, 17) | Median 13, IQR (11, 16) | Median 16, IQR (14, 21) | ||
Quarterly UC cases | Mean 6.1 (variance 9.5) | Mean 5.8 (variance 11.3) | Mean 6.8 (variance 6.2) | 0.3 |
Median 6, IQR (4, 8) | Median 4, IQR (4, 8) | Median 7, IQR (6, 8) | ||
Documented SARS-nCoV2 infection | 8 (1.4%) | 0 | 8 (3.4%) | n.a. |
Gender | 0.7 | |||
Male | 333 (56.7%) | 197 (56.1%) | 136 (57.9%) | |
Female | 253 (43.1%) | 154 (43.9%) | 99 (41.9%) | |
Missing | 1 (0.2%) | 0 | 1 (0.4%) | |
Age at diagnosis | 0.8 | |||
0–4 | 15 (4.3%) | 9 (2.6%) | 4 (1.7%) | |
5–11 | 150 (25.6%) | 92 (26.2%) | 58 (25.6%) | |
12–15 | 211 (35.9%) | 121 (34.5%) | 90 (38.1%) | |
16–21 | 213 (36.3%) | 129 (36.8%) | 84 (35.6%) | |
Institution | 0.01 | |||
Downstate | 36 (6.1%) | 15 (4.3%) | 21 (8.9%) | |
Maimonides | 91 (15.5%) | 63 (17.9%) | 28 (11.9%) | |
Montefiore | 274 (46.7%) | 155 (44.2%) | 119 (50.4%) | |
NYU | 186 (31.7%) | 118 (33.6%) | 68 (28.8%) | |
Race and ethnicity | ||||
White | 278 (47.4%) | 183 (52.1%) | 95 (40.3%) | 0.03 |
Black | 56 (9.5%) | 30 (8.5%) | 26 (11.0%) | 0.2 |
Asian | 31 (5.3%) | 14 (4.0%) | 17 (7.2%) | 0.06 |
Hispanic | 132 (22.5%) | 70 (19.9%) | 62 (26.3%) | 0.02 |
Race missing | 51 (8.7%) | 22 (6.3%) | 29 (12.3%) | |
Ethnicity missing | 69 (11.8%) | 31 (8.8%) | 38 (16.1%) | |
Year of diagnosis | n.a. | |||
2016 | 67 (11.4%) | 67 (19.1%) | 0 (0%) | |
2017 | 85 (14.5%) | 85 (24.2%) | 0 (0%) | |
2018 | 80 (13.6%) | 80 (22.8%) | 0 (0%) | |
2019 | 90 (15.3%) | 90 (25.6%) | 0 (0%) | |
2020 | 97 (16.5%) | 29 (8.3%) | 68 (28.8%) | |
2021 | 102 (17.4%) | 0 (0%) | 102 (43.2%) | |
2022 | 66 (11.2%) | 0 (0%) | 66 (11.2%) | |
Location | 0.3 | |||
Manhattan | 35 (6.0%) | 20 (5.7%) | 15 (6.4%) | |
Brooklyn | 230 (39.2%) | 150 (42.7%) | 80 (33.9%) | |
Queens | 21 (3.6%) | 12 (3.4%) | 9 (3.8%) | |
Bronx | 172 (29.3%) | 100 (28.5%) | 72 (30.5%) | |
Staten Island | 12 (2.0%) | 6 (1.7%) | 6 (2.5%) | |
Westchester | 54 (9.2%) | 28 (8.0%) | 26 (11.0%) | |
Rockland | 36 (6.1%) | 18 (5.1%) | 18 (7.6%) | |
Long Island | 12 (2.0%) | 10 (2.8%) | 2 (0.8%) | |
Other NY or PA or CT or NJ | 5 (0.9%) | 2 (0.6%) | 3 (1.3%) | |
Not reported | 10 (1.7%) | 5 (1.4%) | 5 (2.1%) |
All percentages are column percentages. Race and ethnicity were reported in a free-entry field; they do not add to 100% because patients could be identified with multiple racial and ethnic categories. P value from chi-square test of association between time period (pre-pandemic vs pandemic) and each variable. The distribution of quarterly counts were compared with a Wilcoxon test; we present the means and variances for reference, but the Wilcoxon test does not compare these.
IQR = interquartile range; CT = Connecticut; NJ = New Jersey; NY = New York; NYU = New York University.